Modalis Therapeutics Corp
TSE:4883
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Modalis Therapeutics Corp
Selling, General & Administrative
Modalis Therapeutics Corp
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Modalis Therapeutics Corp
TSE:4883
|
Selling, General & Administrative
-¥231.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Selling, General & Administrative
-¥1.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-7%
|
|
|
GNI Group Ltd
TSE:2160
|
Selling, General & Administrative
-¥19B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-34%
|
|
|
PeptiDream Inc
TSE:4587
|
Selling, General & Administrative
-¥7.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-31%
|
|
|
Takara Bio Inc
TSE:4974
|
Selling, General & Administrative
-¥18.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Selling, General & Administrative
-¥582.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-1%
|
|
Modalis Therapeutics Corp
Glance View
Modalis Therapeutics Corp. engages in the development of gene therapy drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 26 full-time employees. The company went IPO on 2020-08-03. The firm develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The firm has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The firm's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
See Also
What is Modalis Therapeutics Corp's Selling, General & Administrative?
Selling, General & Administrative
-231.8m
JPY
Based on the financial report for Dec 31, 2025, Modalis Therapeutics Corp's Selling, General & Administrative amounts to -231.8m JPY.
What is Modalis Therapeutics Corp's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-2%
Over the last year, the Selling, General & Administrative growth was 6%. The average annual Selling, General & Administrative growth rates for Modalis Therapeutics Corp have been 1% over the past three years , -2% over the past five years .
